Biostage, now known as Harvard Apparatus Regenerative Technology, Inc. (HRGN), is a clinical-stage biotechnology company focused on regenerative medicine. The company specializes in utilizing a patient's own stem cells, which are cultivated on a hollow tubular scaffold, to regenerate damaged organ tissues. This innovative approach aims to address critical medical needs arising from conditions such as cancer, trauma, and congenital defects, particularly in the esophagus and bronchial structures. The Cellspan Esophageal Implant and Cellspan Bronchial Implants are key products in their pipeline, designed to treat severe esophageal diseases and other related conditions.

Recently, HRGN has initiated a Phase 1 clinical trial involving ten patients to evaluate the safety and clinical efficacy of their technologies. The trial is being conducted at prominent medical institutions, including the Mayo Clinic and the University of Michigan, which have been activated to recruit participants. The company has also received FDA approval for its first Investigational New Drug (IND) application, marking a significant milestone in its transition to a clinical-stage entity. Additionally, the European Medicines Agency has approved an Orphan Disease Application for the Cellspan Esophageal Implant, further validating the potential impact of HRGN's regenerative technologies in addressing unmet medical needs.

United States

Biostage is a biotechnology company that focuses on developing organ replacement therapies using cellular scaffolds and tissue engineering.

Biostage

Company Details